1835 related articles for article (PubMed ID: 19243715)
1. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Boellner SW; Stark JG; Krishnan S; Zhang Y
Clin Ther; 2010 Feb; 32(2):252-64. PubMed ID: 20206783
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
7. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
9. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
10. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
Brown TE; Brams M; Gao J; Gasior M; Childress A
Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling RL; Ginsberg LD; Jain R; Gao J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
[TBL] [Abstract][Full Text] [Related]
12. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
[TBL] [Abstract][Full Text] [Related]
13. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
Lopez FA; Ginsberg LD; Arnold V
Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
15. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
Jasinski DR; Krishnan S
J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
19. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
20. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
Childress AC; Sallee FR
Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
